Clinical Pathology Department, Faculty of Human Medicine, Zagazig University, Egypt.
Microbiology and Immunology Department, Faculty of Human Medicine, Zagazig University, Egypt.
Immunobiology. 2021 May;226(3):152074. doi: 10.1016/j.imbio.2021.152074. Epub 2021 Mar 2.
Allergic bronchopulmonary aspergillosis (ABPA) is an allergic respiratory disease. In the current study, we aimed to evaluate the roles of miRNA-21 and miRNA132 as biomarkers in the diagnosis of ABPA. A total of 30 controls, 30 allergic asthmatic patients, 30 severe asthma with fungal sensitization (SAFS) patients, and 30 ABPA patients were included. Real-time polymerase chain reaction was used to quantify the level of miRNAs expression. The expression level of miRNA-21 was significantly higher in allergic asthmatic, SAFS, and ABPA patients in comparison with controls (p < 0.001). However, no significant difference was detected in the expression level of miRNA-21 among the different patient groups (p > 0.05). The ABPA patients had significantly higher levels of miRNA-132 expression compared to controls, allergic asthmatic patients, and SAFS patients (p < 0.001), but there was a non-significant difference between controls and allergic asthmatic patients (p = 0.09). At a cut-off of 1.52, the sensitivity of miRNA-132 expression was 93.3% and the specificity was 100% different ABPA from healthy controls. At a cut-off of 6.5, miRNA-132 expression was found to reliably differentiate between ABPA and SAFS, with a sensitivity of 86.7% and a specificity of 80%. In ABPA patients, miRNA-132 expression positively correlation with the levels of serum IL-5 (r = 0.91, p < 0.001). miRNA-132 has a role in ABPA detection and distinguishing ABPA from allergic asthma and SAFS. These preliminary data from case-control study need further studies to confirm its finding.
变应性支气管肺曲霉病（ABPA）是一种变应性呼吸道疾病。在本研究中，我们旨在评估 microRNA-21 和 microRNA132 作为 ABPA 诊断生物标志物的作用。共纳入 30 名对照者、30 名过敏性哮喘患者、30 名真菌致敏性重症哮喘（SAFS）患者和 30 名 ABPA 患者。采用实时聚合酶链反应定量检测 microRNA 表达水平。与对照组相比，过敏性哮喘、SAFS 和 ABPA 患者的 microRNA-21 表达水平显著升高（p<0.001）。然而，不同患者组之间 microRNA-21 的表达水平无显著差异（p>0.05）。与对照组、过敏性哮喘患者和 SAFS 患者相比，ABPA 患者的 microRNA-132 表达水平显著升高（p<0.001），但对照组与过敏性哮喘患者之间无显著差异（p=0.09）。microRNA-132 表达的截断值为 1.52 时，其对 ABPA 与健康对照组的诊断灵敏度为 93.3%，特异性为 100%。截断值为 6.5 时，microRNA-132 表达可可靠地区分 ABPA 和 SAFS，灵敏度为 86.7%，特异性为 80%。在 ABPA 患者中，microRNA-132 表达与血清 IL-5 水平呈正相关（r=0.91，p<0.001）。microRNA-132 在 ABPA 检测中具有一定作用，可区分 ABPA 与过敏性哮喘和 SAFS。本病例对照研究的初步数据需要进一步研究来证实其发现。
